Len Valentino, MD, President and CEO,
National Hemophilia Foundation
Melissa S. Creary, Ph.D., MPH
Assistant Professor of Health Management & Policy
Senior Director, Office of Public Initiatives
American Thrombosis & Hemostasis Network
Ann Arbor, MI
Judith R. Baker, Dr.PH., MHSA
Public Health Director
Center for Inherited Blood Disorders Orange, CA
Mark Skinner, JD
Institute for Policy Advancement, Washington, DC
Kollet Koulianos, MBA
Senior Director Payer Relations, National Hemophilia Foundation
After completing this activity, the participant should be better able to:
- Discuss the MASAC guidance and 2020 ICER report findings pertaining to new hemophilia therapies.
- Describe some of the current changes in reimbursement policies and potential eligibility challenges to the use of new hemophilia therapies.
- Recognize two individual and system barriers to accessing hemophilia treatment centers for specialized care of patients with bleeding disorders.
- Review the concepts of health equity and inclusion, and how current therapeutic advancements are impacting the ‘traditional’ model of care for patients with bleeding disorders.